Johnson & Johnson (NYSE:JNJ) Earns Daily News Impact Rating of 0.16
Media coverage about Johnson & Johnson (NYSE:JNJ) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.5513334232591 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Is Johnson & Johnson a Safe Stock to Buy? (finance.yahoo.com)
- Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth? (finance.yahoo.com)
- Brokers Issue Forecasts for Johnson & Johnson’s Q2 2018 Earnings (JNJ) (americanbankingnews.com)
- Despite ruling, J&J says Remicade patent battles are not over – Philadelphia Business Journal (bizjournals.com)
- Exclusive: J&J out of race for Pfizer’s $20 billion consumer unit as … – Reuters (reuters.com)
Johnson & Johnson (NYSE JNJ) opened at $145.33 on Monday. Johnson & Johnson has a 12 month low of $111.90 and a 12 month high of $148.32. The stock has a market capitalization of $390,431.97, a PE ratio of 19.91, a PEG ratio of 2.60 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.
JNJ has been the topic of a number of analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target on the stock in a research note on Tuesday, January 23rd. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank of Canada boosted their target price on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. Finally, Jefferies Group upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $146.16.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.